The biotech firm will issue 7.36M ADSs, raising gross proceeds of $920M from its U.S. public offering.
Abivax announced underwriters fully exercised their option to purchase an additional 960K American Depositary Shares (ADSs) in its U.S. public offering. The move brings total ADSs issued to 7.36M, generating approximately $920M in gross proceeds.
The offering follows the company’s initial pricing and reflects strong investor demand. No prior comparable offering size or proceeds were disclosed for context. The funds are expected to support clinical development and operational expansion.
Market reaction details were not provided in the announcement.